Mustang Bio says FDA accepted IND application for MB-109

Mustang Bio announced that the FDA has accepted its Investigational New Drug (IND) application for MB-109, a combination of its MB-101 and MB-108 assets intended for patients with recurrent glioblastoma and high-grade astrocytoma.

Detected & updated continuously · Source: Nebula